000			03615nam a22003615i 4500
001			395139
003			ES-MaUEC
005			20230110120120.0
007			cr nn 008mamaa
008			230103s2022 sz | s |||| 0|eng d
020			_a9783031180705
024	7		_a10.1007/978-3-031-18070-5 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_amRNA Vaccines _cedited by Dong Yu, Benjamin Petsch.
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XI, 205 páginas) _b8 ilustraciones, 7 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aCurrent Topics in Microbiology and Immunology _x2196-9965 _v440
505	0		_aPreface -- mRNA-based vaccines and mode of action -- Self-Amplifying mRNA-Based Vaccine Technology and its Mode of Action -- Formulation and Delivery Technologies for mRNA Vaccines -- Messenger RNA-based vaccines against infectious diseases -- Emerge gate for Therapeutics applications of mRNA based drug -- Clinical Development of mRNA Vaccines: Challenges and Opportunities -- Regulatory Considerations on the Development of mRNA Vaccines.
520			_aThe formulation and the technological advancements in RNA biology, chemistry, stability, and encapsulated delivery systems that have enabled the development of fully synthetic mRNA vaccines are discussed in this volume. The applications of the mRNA technology is covered, focusing on infectious diseases but also touching on other indications, such as immunotherapies and molecular therapies. Potent and long-lasting immune responses observed in animal models, encouraging data from early human clinical studies, together with the success of two mRNA-based COVID-19 vaccines support the use of mRNA-based vaccination as an attractive alternative to conventional vaccine approaches. Consequently, the development progress of the technology, particularly on production, capabilities, and clinical development is reviewed. Topics on safety, regulatory issues, and possible challenges to the mRNA vaccination approach round off this book. Thanks to their high potency, the prospect for generic, low-cost manufacturing processes, and entirely synthetic nature, the future for mRNA vaccines is highly promising. Importantly, mRNA vaccines have the potential to minimize the time between pathogen identification and vaccine release with a huge impact on public health. As the mRNA-based vaccination technology has been progressing rapidly, the book is intended to be an end-to-end review series, covering everything from basic RNA biology and preclinical studies to the manufacturing strategy, clinical development and regulatory approval. It provides established RNA researchers and developers with updates on the latest advancements in the field and allows for a quick but comprehensive overview of this transformative technology, its application, and future potential.
776	0	8	_iPrinted edition: _z9783031180699
776	0	8	_iPrinted edition: _z9783031180712
776	0	8	_iPrinted edition: _z9783031180729
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-18070-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_BiomedLife_2022
999			_c395139 _d395139